Contineum Therapeutics Announces FDA Authorization for PIPE-791, Targeting Chronic Pain Treatment.
Nov 18, 2024
San DiegoManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Product Description
Contineum Therapeutics has received FDA authorization for its Investigational New Drug application for PIPE-791, a treatment aimed at chronic pain conditions, including osteoarthritis and low back pain. The Phase 1b study is set to begin in 2025, with expectations to gather topline data by early 2026.
Company Information
Company
Contineum Therapeutics
Location
San Diego, California, United States
About
Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. The company has a pipeline of internally-developed programs to address multiple NI&I disorders, primarily targeting biological pathways associated with specific clinical impairments. Contineum is headquartered in San Diego, CA.
Fundz sees it the moment Contineum Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma